Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind study of SB17 vs Stelara in plaque psoriasis
2020-006115-19Phase 3Completed
- Sponsor
- Samsung Bioepis
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ustekinumab in plaque psoriasis (2 arms), sponsored by Samsung Bioepis. Primary endpoint: Primary: Percent change from baseline in PASI at Week 12. Started Mar 2021; status: completed.
02
Drugs
ustekinumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2020-006115-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-006115-19.